New Delhi: Strides Shasun has got approval from the US health regulator for pain reliever drug ibuprofen.
The product will be marketed by Strides Pharma Inc in the US market under its OTC brand Nuprin, Strides Shasun said in a BSE filing.
Quoting IRi data, the drug firm said that the US market for ibuprofen tablets USP 200 mg is approximately $520 million.
Strides Shasun stock was trading higher by 4.71 per cent at Rs. 947.95 on the BSE.